Differentiated drug development pipeline with innovative targets and treatment conceptsDeveloping products with high commercial potential and marketability that fulfill important, unmet medical needs

KEY DEVELOPMENT AREA


AGE-RELATED
VASCULAR DISEASES


CU03, CU06 – Macular degeneration


CU06 – Diabetic retinopathy


CU06 – Stroke / Myocardial infarction


INTRACTABLE
METABOLIC DISEASES


CU01 – Renal fibrosis


CU02 – Nonalcoholic steatohepatitis


CU06 – Inflammatory bowel disease


CANCER TARGETING /
IMMUNOTHERAPY


CU04 – Immuno-oncology


CU05 – Lung cancer


CU06 – Immuno-oncology concomitant treatment

Innovative drug development pipeline development strategyDifferentiated R&BD for Fast New Drug Success and Profitability

BUSINESS MODEL